Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Linvoseltamab with or without carfilzomib versus standard-of-care regimens in relapsed/refractory multiple myeloma
NL-OMON59075Phase 3Not yet recruiting
- Sponsor
- Regeneron Pharmaceuticals
- Start
- Mar 2026
- Modality
- Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, Reversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised trial in multiple myeloma (MM) comparing Linvoseltamab monotherapy, Linvoseltamab + carfilzomib and Standard-of-care combination regimen (3 arms). Primary endpoints: Occurrence of treatment-emergent adverse events, Severity of treatment-emergent adverse events and 6 more. Planned start Mar 2026; status: not yet recruiting.
02
Drugs
linvoseltamabcarfilzomib
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NL-OMON59075.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59075.